Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02454777 · ClinicalTrials.gov registry record · NA
High-Intensity Interval Training for Stage I-III Breast Cancer Patients
A NA study, sponsored by University of Southern California.
- Terminated
- Registry status
- NA
- Development phase
- 31
- Enrollment target
NCT02454777 is a NA study that was terminated before completion, run by University of Southern California. The registered enrollment target is 31 participants.
The verdict
NCT02454777, a NA study, was terminated before completion, sponsored by University of Southern California.
- TERMINATED
- Registry status
- NA
- Development phase
- 31 participants
- Enrollment target
Study Summary
This randomized pilot clinical trial studies the feasibility of high-intensity interval training in improving cardiovascular fitness in patients with stage I-III breast cancer undergoing chemotherapy with trastuzumab. Trastuzumab helps patients live longer, but may cause side effects to the heart. Aerobic exercise may help the heart function better, which may help protect it against side effects from trastuzumab. Exercise may also help reduce fatigue and prevent cancer from coming back. High-intensity interval training involves short bursts of higher intensity efforts with longer periods of recovery. This may also allow patients who cannot exercise for a long period of time to still be physically active. This trial studies whether patients can tolerate high-intensity interval training, and how well it works in improving fitness in patients with breast cancer receiving trastuzumab.
Interventions
- OTHER Quality-of-Life Assessment
- OTHER Laboratory Biomarker Analysis
- OTHER Questionnaire Administration
- BEHAVIORAL Exercise Intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2015-09-29 |
| Est. Completion | 2019-07-15 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02454777
The ClinicalTrials.gov registry entry for NCT02454777 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Quality-of-Life Assessment is the first listed.
NCT02454777 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02454777 about?
NCT02454777 is a clinical study titled "High-Intensity Interval Training for Stage I-III Breast Cancer Patients". This randomized pilot clinical trial studies the feasibility of high-intensity interval training in improving cardiovascular fitness in patients with stage I-III breast cancer undergoing chemotherapy with trastuzumab. Trastuzumab helps patients live longer, but may cause side effects to the heart. A...
What is the current status of trial NCT02454777?
This trial is currently terminated. It is a NA study. The enrollment target is 31 participants. The study started on 2015-09-29. Estimated completion is 2019-07-15.
What interventions are being tested in trial NCT02454777?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Laboratory Biomarker Analysis (OTHER), Questionnaire Administration (OTHER), Exercise Intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT02454777?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.